Clinical trials: Advanced and/or Metastatic Solid Tumours
Unspecified Adult Solid Tumor, Protocol Specific
Soblidotin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as soblidotin and gemcitabine, use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00072228
- Testing
- gemcitabine, soblidotin, chemotherapy
- Where
- 2 sites in United States
- Sponsor
- Daiichi Pharmaceuticals
High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors.
- Conditions
- High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
- Trial name
- RAINFOL-01 (NCT05579366)
- Testing
- Rina-S, Carboplatin, Bevacizumab
- Where
- 67 sites in United States, China and 2 more
- Volunteers
- 952 people
- Sponsor
- Genmab
Malignant Solid Tumor
A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
This is an open label Phase 1/2 study, the purpose of the trial is to assess the safety, tolerability, pharmacokinetics, and antitumor activity of ASKB589 in patients suffering from advanced or metastatic solid tumors.
- Trial name
- NCT04632108
- Testing
- ASKB589 Injection
- Where
- 2 sites in China
- Volunteers
- 199 people
- Sponsor
- Jiangsu Aosaikang Pharmaceutical Co., Ltd.
Advanced/Metastatic Solid Tumors
A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients
This is a Phase 1, open-label, dose escalation study in patients with advanced/metastatic solid tumors. Study drug, ADG116, is an anti -CTLA-4 fully human monoclonal antibody that specifically binds to human CTLA-4.
- Trial name
- NCT04501276
- Testing
- ADG116, ADG106, anti PD1 drug
- Where
- 4 sites in United States, Australia
- Volunteers
- 72 people
- Sponsor
- Adagene Inc
Solid Cancers, Non-Hodgkin's Lymphoma
A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
This is an open-label, multicenter, Phase I/II study to assess the safety, tolerability, and pharmacokinetics of GDC-0032. The Phase I portion will be divided into two stages.
- Trial name
- NCT01296555
- Testing
- Fulvestrant, GDC-0032, Letrozole
- Where
- 31 sites in United States, Canada and 2 more
- Volunteers
- 674 people
- Sponsor
- Genentech, Inc.
Solid Tumor, Colorectal Cancer
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers
This study is a first-in-human, Phase 1a/1b, multicenter, open-label study to determine the safety, tolerability, and pharmacokinetics of aplitabart as a single agent and in combination in participants with relapsed and/or…
- Conditions
- Solid Tumor, Colorectal Cancer, Non Hodgkin Lymphoma, Sarcoma
- Trial name
- NCT04553692
- Testing
- Aplitabart (IGM-8444), FOLFIRI, Bevacizumab (and approved biosimilars)
- Where
- 58 sites in United States, Australia and 3 more
- Volunteers
- 272 people
- Sponsor
- IGM Biosciences, Inc.
Cancer, Melanoma
Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors
ONCR-177-101 is a phase 1, open-label, multi-center, dose escalation and expansion study of ONCR-177, an oncolytic Herpes Simplex Virus for intratumoral injection, alone and in combination with PD-1 blockade in adult subjects…
- Conditions
- Cancer, Melanoma, Solid Tumor, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT04348916
- Testing
- ONCR-177, pembrolizumab
- Where
- 11 sites in United States, Canada
- Volunteers
- 66 people
- Sponsor
- Oncorus, Inc.
Solid Tumors, Metastatic Urothelial Carcinoma & Renal Pelvis & Ureter
A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult Patients With Metastatic Urothelial Carcinoma
This is a multi-center, open label, non-randomized Phase 1 study, to be conducted in two parts, Part A, and Part B. Part A in solid tumors included the dose escalation phase for evaluating the safety and tolerability profile of…
- Trial name
- NCT02608125
- Testing
- PRN1371
- Where
- 12 sites in United States, Spain
- Volunteers
- 45 people
- Sponsor
- Principia Biopharma, a Sanofi Company
Gastric Cancer, Gastro-esophageal Junction Cancer
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
This research is designed to determine if experimental treatment with AZD5863, a T cell-engaging bispecific antibody that targets Claudin 18.2 (CLDN18.2) and CD3, is safe, tolerable and has anti-cancer activity in patients with…
- Conditions
- Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- NCT06005493
- Testing
- AZD5863, AZD2936
- Where
- 25 sites in United States, China and 6 more
- Volunteers
- 392 people
- Sponsor
- AstraZeneca
Advanced Solid Tumors
An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
The primary objectives of this trial are to: Characterize the safety and tolerability of TEV-56278 Determine the Recommended Phase 2 Dose (RP2D) Evaluate antitumor activity of TEV-56278 (Part 2 only) Determine the safety and…
- Trial name
- NCT06480552
- Testing
- TEV-56278, Pembrolizumab
- Where
- 12 sites in United States, Canada
- Volunteers
- 240 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Glioma, Glioma, Malignant
Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors
At the time of study termination, NUV-422-02 was a first-in-human, open-label, Phase 1 dose escalation study designed to evaluate the safety and efficacy of NUV-422.
- Conditions
- Glioma, Glioma, Malignant, Glioma, Mixed, Glial Cell Tumors
- Trial name
- NCT04541225
- Testing
- NUV-422
- Where
- 12 sites in United States
- Volunteers
- 74 people
- Sponsor
- Nuvation Bio Inc.
Neoplasm Metastases
A Study to Assess the Potential Effects of Rifampin on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies
The purpose of this study is to evaluate the potential effects of rifampin on blood levels of trabectedin after administration to patients with advanced malignancies.
- Trial name
- NCT01273480
- Testing
- Sequence 1, Sequence 2
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Janssen Research & Development, LLC
Tumors, Lymphoma
A Study Evaluating IV Oncaspar® and IV Gemzar® in the Treatment of Solid Tumors and Lymphoma
This study will research the side effects of pegaspargase (pronounced "peg-as-par-gase"); its brand name is ONCASPAR® when it is used with another FDA-approved cancer treatment (chemotherapy) drug called gemcitabine HCl…
- Trial name
- NCT00363610
- Testing
- Oncaspar & Gemzar; advanced and/or solid tumors and lymphoma
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- Enzon Pharmaceuticals, Inc.
Locally Advanced/Metastatic Solid Tumors
A Study of FL115 Monotherapy in Unresectable or Metastatic Solid Tumors
This is a Phase 1, open-label, multicenter clinical study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of FL115 administered as monotherapy in subjects with unresectable…
- Trial name
- NCT07131189
- Testing
- FL115
- Where
- 3 sites in China
- Volunteers
- 30 people
- Sponsor
- Suzhou Forlong Biotechnology Co., Ltd
Gastrointestinal Stromal Tumors, GIST
A Drug-drug Interaction Study of Avapritinib and Midazolam
The purpose of this study is to investigate the effect of multiple dosing of avapritinib on the pharmacokinetics (PK) of midazolam in adult patients with metastatic or unresectable gastrointestinal stromal tumors (GIST)…
- Conditions
- Gastrointestinal Stromal Tumors, GIST, Non-resectable Advanced Solid Tumors, Recurrent or Unresectable Central Nervous System (CNS) Tumors
- Trial name
- NCT04908176
- Testing
- Avapritinib, midazolam
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Blueprint Medicines Corporation
Gastric Cancer, Triple Negative Breast Cancer
A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment
This is a a Multicenter, Open-label, Single-arm, Phase Ib Dose Escalation and Multi-cohort Expansion Clinical Study to Assess the Safety and Antitumor Activity of Niraparib in Combination with MGD013 in Patients with Advanced or…
- Conditions
- Gastric Cancer, Triple Negative Breast Cancer, Biliary Tract Carcinoma, Endometrial Carcinoma
- Trial name
- NCT04178460
- Testing
- Niraparib combined with MGD013
- Where
- 19 sites in China
- Volunteers
- 60 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Advanced Solid Tumor, Locally Advanced Solid Tumor
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
TransCon IL-2 β/γ is an investigational drug being developed for treatment of locally advanced or metastatic solid tumors. This is a first-in-human, open-label, Phase 1/2, dose escalation and dose expansion study of TransCon IL-2…
- Conditions
- Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Platinum-resistant Ovarian Cancer
- Trial name
- IL Believe (NCT05081609)
- Testing
- TransCon IL-2 β/γ, Pembrolizumab, Chemotherapy drug
- Where
- 68 sites in United States, Australia and 8 more
- Volunteers
- 320 people
- Sponsor
- Ascendis Pharma Oncology Division A/S
Solid Tumor
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
This was an open-label, nonrandomized, Phase 1/2 study designed to determine the safety, tolerability, and efficacy of epacadostat when given in combination with pembrolizumab and 7 different chemotherapy regimens described as…
- Trial name
- NCT03085914
- Testing
- Epacadostat, Pembrolizumab, Oxaliplatin
- Where
- 16 sites in United States
- Volunteers
- 70 people
- Sponsor
- Incyte Corporation
Advanced or Metastatic Solid Tumors, Triple Negative Breast Cancer (TNBC)
A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
This is a Phase 1, first-in-human (FIH), open-label, multicenter study designed to evaluate the safety, tolerability, PK, and preliminary anti-tumor activity of SHY-ONC6 in participants with advanced or metastatic solid tumors…
- Conditions
- Advanced or Metastatic Solid Tumors, Triple Negative Breast Cancer (TNBC), HR+ Breast Cancer, Colon Cancer
- Trial name
- Luca-1 (NCT07705334)
- Testing
- SHY-ONC6
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- SHY Therapeutics
Selected Advanced Solid Tumors
A First-in-Human Open-label, Phase I/Ib Dose Escalation and Expansion Cohort Study of EOS006215 as Monotherapy and in Combination With Pembrolizumab or Other Anticancer Treatments in Participants With Advanced Solid Tumors
TRM-010 is a first-in-human (FIH) clinical study designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of EOS006215, a fully human monoclonal antibody that…
- Trial name
- NCT06877533
- Testing
- EOS006215, Anticancer agent
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- iTeos Belgium SA
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.